Тромбоцитопении от 3 и 4 степен са наблюдавани при 14% от пациентите, получаващи TMZ.
Grade 3 or Grade 4 thrombocyte abnormalities, including thrombocytopenic events were observed in 14% of the patients who received TMZ.